Sistemic Ltd., the fast growing UK life sciences company, today launched their patented SistemQC™ services for researchers and industry. SistemQC™ monitors cells including stem cell populations for intended or unintended change using biologically defined measures. These new product additions will support faster decision making for cell manufacturers at critical QC points within their process workflows. This allows them to proceed with confidence that their cell populations are being reliably and informatively measured. With even slightly delayed production costs often running into millions of dollars, the potential for SistemQC to have a major impact is clear.
SistemQC™ utilises Sistemic's enabling platform technology SistemRNA™, which profiles microRNA expression providing a fingerprint of the cell system. This informs on the current cell population phenotype giving confidence that it has not deviated from the expected phenotype. SistemQC™ is suitable for use in all cells including BHK, CHO, HEK-293, NS0, PER.C6 and hybridomas.
Prof. Chris Hillier, CEO says "SistemQC™ services are being launched in response to the unmet need in the cell and stem cell fields: "In our conversations with both researchers and pharma over the last 12 months, it has become apparent that there is a real demand for reliable, information-rich QC methods to monitor cells easily and effectively and to fit within current workflow processes. Importantly, SistemQC™ not only gives a succinct read out on the status of the cells but also an insight into the underlying biological effects associated with any change detected. We are now launching our service to US customers through our Boston office and the rest of the world will follow shortly."
Immunotherapy timing key to survival in small cell lung cancer treatment